CDK inhibitors in cancer therapy: what is next?

The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2008-01, Vol.29 (1), p.16-21
Hauptverfasser:	Malumbres, Marcos, Pevarello, Paolo, Barbacid, Mariano, Bischoff, James R
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Cycle - drug effects Clinical Trials as Topic Cyclin-Dependent Kinases - antagonists & inhibitors Drug Delivery Systems Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Humans Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	21
container_issue	1
container_start_page	16
container_title	Trends in pharmacological sciences (Regular ed.)
container_volume	29
creator	Malumbres, Marcos Pevarello, Paolo Barbacid, Mariano Bischoff, James R
description	The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation inhibitors are now in clinical trials. Future approaches to determine clinical benefit need to incorporate both the lessons learned from these early compounds and information recently obtained from the genetic analysis of CDKs in preclinical models. Here we discuss key concepts that should be considered when validating the clinical utility of CDK inhibitors in cancer therapy.
doi_str_mv	10.1016/j.tips.2007.10.012
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70196351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165614707002751</els_id><sourcerecordid>70196351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d319e28ed42678451737adb0208b72d27969df7b1a9b877dccfbf02a3a40d4913</originalsourceid><addsrcrecordid>eNp9kV1LwzAUhoMobn78AS-kV951O0naphVRZH7iwAv1OqTJKcvs2pl06v69KRsIXniVcHjeF85zCDmhMKJAs_F81NmlHzEAEQYjoGyHDGkueMwFT3fJMEBpnNFEDMiB93MA4JzRfTKgOaRJDjAk48nNU2SbmS1t1zofvpFWjUYXdTN0ark-j75mqousjxr87q6OyF6lao_H2_eQvN3dvk4e4unz_ePkehrrRKRdbDgtkOVoEpaJPEmp4EKZEhjkpWCGiSIrTCVKqooyF8JoXZUVMMVVAiYpKD8kZ5vepWs_Vug7ubBeY12rBtuVlwJokfG0B9kG1K713mEll84ulFtLCrLXJOey1yR7Tf0saAqh0237qlyg-Y1svQTgYgNg2PHTopNeWwxejHWoO2la-3__5Z-4rm1jtarfcY1-3q5cE-xJKj2TIF_6Q_V3AgHARNjqB1xPi7Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70196351</pqid></control><display><type>article</type><title>CDK inhibitors in cancer therapy: what is next?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Malumbres, Marcos ; Pevarello, Paolo ; Barbacid, Mariano ; Bischoff, James R</creator><creatorcontrib>Malumbres, Marcos ; Pevarello, Paolo ; Barbacid, Mariano ; Bischoff, James R</creatorcontrib><description>The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation inhibitors are now in clinical trials. Future approaches to determine clinical benefit need to incorporate both the lessons learned from these early compounds and information recently obtained from the genetic analysis of CDKs in preclinical models. Here we discuss key concepts that should be considered when validating the clinical utility of CDK inhibitors in cancer therapy.</description><identifier>ISSN: 0165-6147</identifier><identifier>EISSN: 1873-3735</identifier><identifier>DOI: 10.1016/j.tips.2007.10.012</identifier><identifier>PMID: 18054800</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Advanced Basic Science ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cell Cycle - drug effects ; Clinical Trials as Topic ; Cyclin-Dependent Kinases - antagonists & inhibitors ; Drug Delivery Systems ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Humans ; Neoplasms - drug therapy</subject><ispartof>Trends in pharmacological sciences (Regular ed.), 2008-01, Vol.29 (1), p.16-21</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d319e28ed42678451737adb0208b72d27969df7b1a9b877dccfbf02a3a40d4913</citedby><cites>FETCH-LOGICAL-c475t-d319e28ed42678451737adb0208b72d27969df7b1a9b877dccfbf02a3a40d4913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tips.2007.10.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18054800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malumbres, Marcos</creatorcontrib><creatorcontrib>Pevarello, Paolo</creatorcontrib><creatorcontrib>Barbacid, Mariano</creatorcontrib><creatorcontrib>Bischoff, James R</creatorcontrib><title>CDK inhibitors in cancer therapy: what is next?</title><title>Trends in pharmacological sciences (Regular ed.)</title><addtitle>Trends Pharmacol Sci</addtitle><description>The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation inhibitors are now in clinical trials. Future approaches to determine clinical benefit need to incorporate both the lessons learned from these early compounds and information recently obtained from the genetic analysis of CDKs in preclinical models. Here we discuss key concepts that should be considered when validating the clinical utility of CDK inhibitors in cancer therapy.</description><subject>Advanced Basic Science</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Cycle - drug effects</subject><subject>Clinical Trials as Topic</subject><subject>Cyclin-Dependent Kinases - antagonists & inhibitors</subject><subject>Drug Delivery Systems</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><issn>0165-6147</issn><issn>1873-3735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV1LwzAUhoMobn78AS-kV951O0naphVRZH7iwAv1OqTJKcvs2pl06v69KRsIXniVcHjeF85zCDmhMKJAs_F81NmlHzEAEQYjoGyHDGkueMwFT3fJMEBpnNFEDMiB93MA4JzRfTKgOaRJDjAk48nNU2SbmS1t1zofvpFWjUYXdTN0ark-j75mqousjxr87q6OyF6lao_H2_eQvN3dvk4e4unz_ePkehrrRKRdbDgtkOVoEpaJPEmp4EKZEhjkpWCGiSIrTCVKqooyF8JoXZUVMMVVAiYpKD8kZ5vepWs_Vug7ubBeY12rBtuVlwJokfG0B9kG1K713mEll84ulFtLCrLXJOey1yR7Tf0saAqh0237qlyg-Y1svQTgYgNg2PHTopNeWwxejHWoO2la-3__5Z-4rm1jtarfcY1-3q5cE-xJKj2TIF_6Q_V3AgHARNjqB1xPi7Y</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Malumbres, Marcos</creator><creator>Pevarello, Paolo</creator><creator>Barbacid, Mariano</creator><creator>Bischoff, James R</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>CDK inhibitors in cancer therapy: what is next?</title><author>Malumbres, Marcos ; Pevarello, Paolo ; Barbacid, Mariano ; Bischoff, James R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d319e28ed42678451737adb0208b72d27969df7b1a9b877dccfbf02a3a40d4913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Advanced Basic Science</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Cycle - drug effects</topic><topic>Clinical Trials as Topic</topic><topic>Cyclin-Dependent Kinases - antagonists & inhibitors</topic><topic>Drug Delivery Systems</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malumbres, Marcos</creatorcontrib><creatorcontrib>Pevarello, Paolo</creatorcontrib><creatorcontrib>Barbacid, Mariano</creatorcontrib><creatorcontrib>Bischoff, James R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malumbres, Marcos</au><au>Pevarello, Paolo</au><au>Barbacid, Mariano</au><au>Bischoff, James R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDK inhibitors in cancer therapy: what is next?</atitle><jtitle>Trends in pharmacological sciences (Regular ed.)</jtitle><addtitle>Trends Pharmacol Sci</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>29</volume><issue>1</issue><spage>16</spage><epage>21</epage><pages>16-21</pages><issn>0165-6147</issn><eissn>1873-3735</eissn><abstract>The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation inhibitors are now in clinical trials. Future approaches to determine clinical benefit need to incorporate both the lessons learned from these early compounds and information recently obtained from the genetic analysis of CDKs in preclinical models. Here we discuss key concepts that should be considered when validating the clinical utility of CDK inhibitors in cancer therapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>18054800</pmid><doi>10.1016/j.tips.2007.10.012</doi><tpages>6</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0165-6147
ispartof	Trends in pharmacological sciences (Regular ed.), 2008-01, Vol.29 (1), p.16-21
issn	0165-6147 1873-3735
language	eng
recordid	cdi_proquest_miscellaneous_70196351
source	MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects	Advanced Basic Science Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Cycle - drug effects Clinical Trials as Topic Cyclin-Dependent Kinases - antagonists & inhibitors Drug Delivery Systems Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Humans Neoplasms - drug therapy
title	CDK inhibitors in cancer therapy: what is next?
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A07%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDK%20inhibitors%20in%20cancer%20therapy:%20what%20is%20next?&rft.jtitle=Trends%20in%20pharmacological%20sciences%20(Regular%20ed.)&rft.au=Malumbres,%20Marcos&rft.date=2008-01-01&rft.volume=29&rft.issue=1&rft.spage=16&rft.epage=21&rft.pages=16-21&rft.issn=0165-6147&rft.eissn=1873-3735&rft_id=info:doi/10.1016/j.tips.2007.10.012&rft_dat=%3Cproquest_cross%3E70196351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70196351&rft_id=info:pmid/18054800&rft_els_id=S0165614707002751&rfr_iscdi=true